SLXN
Silexion Therapeutics Corp
Key Financials
Net Income
$-11912000
↑ 27.9%
Operating Income
$-11632000
↑ 7.5%
Shareholders' Equity
$2.6M
↑ 165.3%
EPS (Diluted)
$8.96
↓ 66.0%
Total Liabilities
$4.6M
↓ 32.7%
Cash & Equivalents
$6.0M
↑ 404.7%
Total Assets
$7.2M
↑ 152.0%
Operating Cash Flow
$-10819000.00
↓ 28.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| PRE 14A | 8/14/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| 8-K | 8/14/2026 | View on SEC |
| 8-K | 8/13/2026 | View on SEC |
| 8-K | 8/13/2026 | View on SEC |
| 424B4 | 8/13/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| EFFECT | 8/11/2026 | View on SEC |
| S-1/A | 8/10/2026 | View on SEC |
| 8-K | 8/10/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SLXN |
| Company Name | Silexion Therapeutics Corp |
| CIK | 2022416 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | E9 |
| Phone | 972-8-6286005 |